AM

AMGN

NasdaqGS

Amgen Inc.

Healthcare
Drug Manufacturers - General
United States
447.10USD
-10.83 (-2.36%)
Market Cap: 247.57B USD

Revenue and Net Income

Values in USD

Income Statement

Values in USD

Financial itemTTMSep 30, 2026Dec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022
Total Revenue
38.90B36.75B33.42B28.19B26.32B
Cost of Revenue
11.32B12.04B12.86B8.45B6.41B
Gross Profit
27.58B24.71B20.57B19.74B19.92B
Operating Expense
14.97B15.63B13.31B11.84B10.35B
Operating Income
12.61B9.08B7.26B7.90B9.57B
Net Non Operating Interest Income Expense
-2.64B-2.75B-3.15B-2.88B-1.41B
Other Income Expense
1.08B2.65B506.00M2.83B-814.00M
Pretax Income
11.05B8.98B4.61B7.86B7.35B
Tax Provision
1.66B1.26B519.00M1.14B794.00M
Net Income Common Stockholders
9.39B7.71B4.09B6.72B6.55B
Diluted NI Available to Com Stockholders
9.39B7.71B4.09B6.72B6.55B
Basic EPS
17.3914.337.6212.5612.18
Diluted EPS
17.2514.237.5612.4912.11
Basic Average Shares
539.50M538.00M537.00M535.00M538.00M
Diluted Average Shares
544.25M542.00M541.00M538.00M541.00M
Total Operating Income as Reported
12.61B9.08B7.26B7.90B9.57B
Total Expenses
26.29B27.67B26.17B20.29B16.76B
Net Income from Continuing & Discontinued Operation
9.39B7.71B4.09B6.72B6.55B
Normalized Income
9.39B7.71B4.09B6.72B6.55B
Interest Expense
2.64B2.75B3.15B2.88B1.41B
Net Interest Income
-2.64B-2.75B-3.15B-2.88B-1.41B
EBIT
13.69B11.73B7.76B10.73B8.75B
EBITDA
18.17B16.90B13.36B14.80B12.17B
Reconciled Cost of Revenue
11.32B12.04B12.86B8.45B6.41B
Reconciled Depreciation
4.48B5.17B5.59B4.07B3.42B
Net Income from Continuing Operation Net Minority Interest
9.39B7.71B4.09B6.72B6.55B
Total Unusual Items Excluding Goodwill
———0.000.00
Total Unusual Items
———0.000.00
Normalized EBITDA
18.17B16.90B13.36B14.80B12.17B
Tax Rate for Calcs
0.150.140.110.140.11
Tax Effect of Unusual Items
0.000.000.000.000.00

Key Statistics

Valuation

Market Cap (USD)247.57B
Market Cap (Local)247.57B
P/E (TTM)26.36
P/S (TTM)6.36
MC/EBITDA13.63

Volume & Shares

Last Volume2.03M
Avg Vol (10D)2.19M
Avg Vol (30D)2.67M
Avg Vol (90D)2.80M
Shares Outstanding540.63M

Growth Indicators

Revenue TTM/Ann1.06
Net Income TTM/Ann1.22
EBITDA TTM/Ann1.08
Gross Profit TTM/Ann1.12
Operating Inc TTM/Ann1.39

Currency & Exchange

Trading CurrencyUSD
Financial CurrencyUSD
Trading/USD Rate1.00
Financial/USD Rate1.00
ExchangeNasdaqGS

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease Prolia to treat postmenopausal women with osteoporosis XGEVA for skeletal-related events prevention Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization Nplate for the treatment of patients with immune thrombocytopenia KYPROLIS to treat patients with relapsed or refractory multiple myeloma Aranesp to treat a lower-than-normal number of red blood cells and anemia EVENITY for the treatment of osteoporosis in postmenopausal for women Vectibix to treat patients with wild-type RAS metastatic colorectal cancer BLINCYTO for the treatment of patients with acute lymphoblastic leukemia TEPEZZA to treat thyroid eye disease and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE BEONE MEDICINES LTD. to develop and commercialize Aimovig UCB for the development and commercialization of EVENITY Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.